瑞马唑仑与七氟烷用于全身麻醉:血流动力学与临床结局的Meta分析及试验序贯分析
瑞马唑仑显著降低术中低血压风险(RR 0.38,95%CI 0.25–0.57,P<0.001),MAP和HR差异仅见于特定时间点;PONV降低在敏感性分析中提示但主要分析未达统计学显著,需谨慎解读。
要点
- 瑞马唑仑较七氟烷显著降低术中低血压风险(RR 0.38)。
- MAP在手术开始后30分钟瑞马唑仑组较高(均差6.05 mmHg)。
- PONV降低仅见于敏感性分析,主要分析未达显著,需谨慎。
核心结论
- 瑞马唑仑与七氟烷相比术中低血压发生率更低,MAP和HR差异仅限特定时间点。
- 敏感性分析提示瑞马唑仑可能减少PONV,但主要分析未达统计学显著,应谨慎解读。
研究设计与样本
- 系统评价与随机对照试验(RCT)的Meta分析,并采用试验序贯分析(TSA)。
- 检索PubMed/MEDLINE、Embase、Cochrane CENTRAL、Web of Science和Scopus,从建库至2025年4月。
主要发现
- 瑞马唑仑显著降低术中低血压(二分类事件)风险:RR 0.38,95%CI 0.25–0.57,P<0.001。
- 手术开始后30分钟瑞马唑仑组平均动脉压(MAP)较高:均差6.05 mmHg,P<0.03。
- 瑞马唑仑组心率(HR)在30分钟(P=0.04)、手术结束(P<0.01)和麻醉后监护室(P<0.01)均较高。
- 敏感性分析提示瑞马唑仑降低24小时PONV:RR 0.65(95%CI 0.47–0.90),P=0.01;72小时:RR 0.66(95%CI 0.50–0.89)。
- TSA仅确认瑞马唑仑在降低术中低血压方面获益。
关键数值与推荐
- 纳入标准:比较术中瑞马唑仑与七氟烷且报告术中或术后结局的RCT;排除会议摘要。
临床怎么用
- 对于关注术中血流动力学稳定的全身麻醉,瑞马唑仑可考虑作为七氟烷的替代选择以降低低血压风险。
- 瑞马唑仑对PONV的潜在获益证据尚不充分,不应作为主要决策依据。
局限性
- PONV降低在主要分析中未达统计学显著,需谨慎解读。
- MAP和HR差异仅见于特定时间点,整体血流动力学优势有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Remimazolam is a novel ultra-short-acting intravenous benzodiazepine, while sevoflurane is a widely used inhalational anaesthetic for general anaesthesia (GA). Both agents are associated with risks of haemodynamic instability and postoperative nausea and vomiting (PONV), which can affect patient safety and recovery. OBJECTIVE: To compare the efficacy and safety of remimazolam versus sevoflurane in terms of intraoperative haemodynamic stability during the maintenance phase of GA or deep sedation, and the incidence of PONV. DESIGN: Systematic review of randomised controlled trials (RCTs) and meta-analysis, with trial sequential analysis (TSA). DATA SOURCES: PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science and Scopus were systematically searched from inception to April 2025. ELIGIBILITY CRITERIA: RCTs comparing intraoperative use of remimazolam and sevoflurane with reported intraoperative or postoperative outcomes. Conference abstracts were excluded. RESULTS: Twelve RCTs ( n = 739 patients; mean age 61.6 years; 36.8% laparoscopic procedures) were included. Remimazolam significantly reduced the risk of intraoperative hypotension (as a binary event) compared with sevoflurane [risk ratio (RR) 0.38, 95% confidence interval (CI) 0.25 to 0.57; P < 0.001]. Mean arterial pressure (MAP) was higher with remimazolam at 30 min after start of surgery (mean difference 6.05 mmHg, P < 0.03). Heart rate (HR) was consistently higher with remimazolam at 30 min ( P = 0.04), at the end of surgery ( P < 0.01) and in the postanaesthesia care unit ( P < 0.01). Analyses suggested a reduction in PONV incidence up to 24 h with remimazolam [RR 0.65 (95% CI, 0.47 to 0.90); P = 0.01] and 72 h [RR 0.66 (95% CI, 0.50 to 0.89)]. TSA just confirmed favouring remimazolam in reducing intraoperative hypotension. CONCLUSIONS: Remimazolam was associated with a lower incidence of intraoperative hypotension compared with sevoflurane, while differences in MAP and HR were limited to specific time points. Sensitivity analyses suggested a potential reduction in PONV; however, these findings were not statistically significant in the primary analysis and should be interpreted with caution.
引用
- Takayama LT, de Souza K, Batista da Hora DA, et al. Remimazolam versus sevoflurane for general anaesthesia: A meta-analysis with trial sequential analysis of haemodynamic and clinical outcomes. Eur J Anaesthesiol. 2026. PMID: 42693830. doi:10.1097/EJA.0000000000002412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。